

RemeGen (9995 HK)

Strong sales in Q3, with a narrowed net loss

In 3Q24, RemeGen achieved robust product sales, with revenue reaching a record high of RMB467mn (+14% QoQ, +35% YoY), driven by product sales of RC18 (~RMB270mn, +43% YoY) and RC48 (~RMB200mn, +25% YoY). Total revenue in 9M24 was RMB1,209mn (+57% YoY), representing approximately 73% of our previous FY24 estimate, aligning with our expectations. We are reassured that the Company will meet its FY24 sales target of a 50%+ YoY increase, and expect the strong sales momentum to continue in 4Q24 and beyond. GP margin improved to 82.1% in 3Q24 (vs 78.3% in 1H24). RemeGen's SG&A expense ratio decreased to 68.5% in 3Q24 from 72.4% in 1H24. In 3Q24, the R&D expense was RMB347mn, down 27% QoQ vs RMB475mn in 2Q24, due to pipeline optimization and R&D team restructuring. The Company narrowed its net loss to RMB291mn in 3Q24, vs RMB432mn in 2Q24. In 3Q24, net cash spending from operations narrowed to RMB15mn, vs RMB394mn in 2Q24. As of Sep 2024, RemeGen had a cash balance of RMB925mn (incl. financial assets), RMB1,027mn of short-term borrowings, and RMB1,341mn of long-term borrowings, which were largely consistent with the balance as of end-Jun 2024, indicating a proper cash control in 3Q, though there was a need for further financing.

- Looking forward to RC18's global development.** We expect RemeGen to unblind the first-stage of RC18's Ph3 global SLE trial (NCT05306574) in 1H25 after a 52-week treatment period for the 90 enrolled patients. Concurrently, the enrolment for the second stage of the Ph3 study is underway with FPI expected in 4Q24. A parallel global Ph3 study of RC18 in SLE (NCT06456567) has also been registered. RemeGen is conducting a global Ph3 trial of RC18 for MG in the US with FPI in Aug 2024. In China, approved for SLE and RA already, the BLA for MG was submitted in Oct 2024 with priority review, and the Ph3 trials for pSS and IgAN also completed enrolment with BLA submission expected in 2025. The Ph3 trial in IgAN is expected to read out the UPCR data in 1H25. We anticipate that RC18 holds potential for global collaboration, albeit with some uncertainties.
- Smooth clinical progress of RC48 globally.** Pfizer is actively conducting a pivotal Ph2 trial of RC48 monotherapy in 2L HER2-expressing UC and a Ph3 trial of RC48 + Keytruda in 1L HER2-expressing UC. The timeline of BLA submission of the Ph2 pivotal trial is tied to the progress of the Ph3 trial. In China, RC48 has already been approved for 2L+ UC and 3L GC with NRDL coverage. The BLA of RC48 for HER2-positive BC with liver metastasis was submitted in Oct 2024 and detailed data of the Ph3 study are to be released at the SABCS meeting in Dec 2024. A Ph3 trial of RC48 in HER2-low BC is currently ongoing with data readout expected in 1Q25. To expand RC48's use for front-line treatment, a Ph3 trial of RC48+toripalimab for 1L HER2-expressing UC is ongoing with data readout in 1H25. RemeGen is planning a Ph3 trial of RC48 in 1L GC.
- Maintain BUY.** We believe that the rapid growth in product revenue will help to alleviate the Company's cash flow risks. We revise up our DCF-based TP from HK\$19.59 to HK\$21.09 (WACC: 12.93%, terminal growth rate: 2.0%).

Earnings Summary

(YE 31 Dec)	FY22A	FY23A	FY24E	FY25E	FY26E
Revenue (RMB mn)	768	1,076	1,740	2,635	3,952
YoY growth (%)	(46.1)	40.2	61.7	51.4	50.0
Net profit (RMB mn)	(998.8)	(1,511.2)	(1,268.4)	(967.1)	(275.2)
EPS (Reported) (RMB)	(1.88)	(2.80)	(2.33)	(1.78)	(0.51)
R&D expenses (RMB mn)	(982)	(1,306)	(1,450)	(1,450)	(1,502)
Admin expenses (RMB mn)	(273)	(314)	(336)	(429)	(526)

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price	HK\$21.09
(Previous TP)	HK\$19.59
Up/Downside	28.0%
Current Price	HK\$16.48

China Healthcare

Jill WU, CFA

(852) 3900 0842
jillwu@cmbi.com.hk

Andy WANG

(852) 3657 6288
andywang@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	8,970.6
Avg 3 mths t/o (HK\$ mn)	42.5
52w High/Low (HK\$)	47.50/10.62
Total Issued Shares (mn)	544.3

Source: FactSet

Shareholding Structure

HKSCC nominees limited	34.8%
Yantai Rongda	18.8%


Source: HKEx

Share Performance

	Absolute	Relative
1-mth	-3.6%	-0.1%
3-mth	24.3%	3.7%
6-mth	-41.0%	-48.6%

Source: FactSet

12-mth Price Performance



Source: FactSet

Figure 1: Risk-adjusted DCF valuation

DCF Valuation (RMB mn)	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E
EBIT	-1,203	-853	-129	468	1,225	2,026	2,833	3,495	3,958	3,918	3,694	3,645
Tax rate	0%	0%	0%	15%	15%	15%	15%	15%	15%	15%	15%	15%
EBIT*(1-tax rate)	-1,203	-853	-129	397	1,042	1,722	2,408	2,971	3,364	3,330	3,140	3,099
+ D&A	265	272	272	271	271	270	270	269	269	269	268	268
- Change in working capital	506	-233	-351	-284	-333	-309	-247	-184	-210	143	201	75
- Capex	-600	-400	-200	-200	-200	-200	-200	-200	-200	-200	-200	-200
FCFF	-1,032	-1,214	-408	185	780	1,483	2,231	2,856	3,224	3,542	3,410	3,241
Terminal value												30,248
FCF + Terminal value	-1,032	-1,214	-408	185	780	1,483	2,231	2,856	3,224	3,542	3,410	33,490
PV of enterprise (RMB mn)	11,944											
Net debt (RMB mn)	1,612											
Equity value (RMB mn)	10,332											
No. of shares (mn)	544											
DCF per shares (RMB)	18.98											
DCF per share (HK\$)	21.09											
Terminal growth rate	2.0%											
WACC	12.93%											
Cost of Equity	16.7%											
Cost of Debt	5.0%											
Equity Beta	1.3											
Risk Free Rate	3.0%											
Market Risk Premium	10.5%											
Target Debt to Asset ratio	30.0%											
Effective Corporate Tax Rate	15.0%											

Source: CMBIGM estimates

Figure 2: Sensitivity analysis (HK\$)

Terminal growth rate	WACC				
	11.93%	12.43%	12.93%	13.43%	13.93%
3.0%	27.57	24.99	22.69	20.63	18.78
2.5%	26.43	24.01	21.85	19.91	18.15
2.0%	25.41	23.13	21.09	19.24	17.57
1.5%	24.48	22.33	20.39	18.64	17.04
1.0%	23.64	21.60	19.76	18.08	16.55

Source: CMBIGM estimates

Figure 3: CMBIGM estimates revision

RMB mn	New			Old			Diff (%)		
	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
Revenue	1,740	2,635	3,952	1,667	2,709	3,797	4%	-3%	4%
Gross profit	1,397	2,138	3,193	1,288	2,115	2,978	8%	1%	7%
Operating profit	-1,203	-853	-129	-1,544	-1,032	-288	N/A	N/A	N/A
Net profit	-1,268	-967	-275	-1,609	-1,146	-434	N/A	N/A	N/A
EPS (RMB)	(2.33)	(1.78)	(0.51)	(2.96)	(2.11)	(0.80)	N/A	N/A	N/A
Gross margin	80.31%	81.15%	80.81%	77.29%	78.09%	78.42%	+3.02 ppt	+3.06 ppt	+2.39 ppt

Source: Company data, CMBIGM estimates

Figure 4: CMBIGM estimates vs consensus

RMB mn	CMBIGM			Consensus			Diff (%)		
	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
Revenue	1,740	2,635	3,952	1,662	2,392	3,262	5%	10%	21%
Gross profit	1,397	2,138	3,193	1,312	1,943	2,667	6%	10%	20%
Operating profit	-1,203	-853	-129	-1,479	-967	-339	N/A	N/A	N/A
Net profit	-1,268	-967	-275	-1,529	-1,070	-507	N/A	N/A	N/A
EPS (RMB)	(2.33)	(1.78)	(0.51)	(2.78)	(1.81)	(0.59)	N/A	N/A	N/A
Gross margin	80.31%	81.15%	80.81%	78.96%	81.22%	81.75%	+1.35 ppt	-0.07 ppt	-0.94 ppt

Source: Company data, Bloomberg, CMBIGM estimates

Financial Summary

INCOME STATEMENT	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Revenue	1,424	768	1,076	1,740	2,635	3,952
Cost of goods sold	(67)	(270)	(253)	(343)	(497)	(758)
Gross profit	1,357	498	823	1,397	2,138	3,193
Operating expenses	(1,080)	(1,497)	(2,334)	(2,666)	(3,105)	(3,468)
Selling expense	(263)	(441)	(775)	(896)	(1,199)	(1,383)
Admin expense	(220)	(273)	(314)	(336)	(429)	(526)
R&D expense	(711)	(982)	(1,306)	(1,450)	(1,450)	(1,502)
Others	113	199	61	16	(27)	(58)
Operating profit	282	(992)	(1,488)	(1,203)	(853)	(129)
Interest income	(5)	(7)	(23)	(65)	(114)	(146)
Pre-tax profit	276	(999)	(1,511)	(1,268)	(967)	(275)
Income tax	0	0	0	0	0	0
Minority interest	0	0	0	0	0	0
Net profit	276	(999)	(1,511)	(1,268)	(967)	(275)

BALANCE SHEET	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Current assets	2,300	3,212	2,229	2,221	2,726	3,188
Cash & equivalents	1,757	2,069	727	1,131	1,306	1,254
Account receivables	7	281	420	327	495	742
Inventories	280	523	742	422	585	852
Financial assets at FVTPL	0	0	0	0	0	0
Other current assets	256	339	340	340	340	340
Non-current assets	1,859	2,809	3,295	3,713	3,924	3,936
PP&E	1,578	2,407	2,833	3,235	3,425	3,416
Right-of-use assets	149	205	252	271	291	311
Intangibles	13	17	24	21	23	24
Financial assets at FVTPL	12	80	94	94	94	94
Other non-current assets	108	100	92	92	92	92
Total assets	4,159	6,021	5,524	5,934	6,650	7,124
Current liabilities	616	892	1,138	1,231	1,328	1,492
Short-term borrowings	0	0	286	286	286	286
Account payables	159	222	139	232	330	494
Other current liabilities	405	610	653	653	653	653
Lease liabilities	52	60	58	58	58	58
Non-current liabilities	96	149	953	2,453	3,953	4,453
Long-term borrowings	0	0	841	2,341	3,841	4,341
Deferred income	46	44	37	37	37	37
Other non-current liabilities	51	105	76	76	76	76
Total liabilities	713	1,041	2,091	3,684	5,282	5,945
Share capital	490	544	544	544	544	544
Other reserves	2,957	4,436	2,893	1,710	829	639
Total shareholders equity	3,446	4,980	3,437	2,254	1,373	1,183
Total equity and liabilities	4,159	6,021	5,528	5,938	6,654	7,128

CASH FLOW	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Operating						
Profit before taxation	276	(999)	(1,511)	(1,268)	(967)	(275)
Depreciation & amortization	65	121	174	198	210	209
Tax paid	0	0	0	0	0	0
Change in working capital	(168)	(524)	(358)	506	(233)	(351)
Others	90	138	194	217	262	294
Net cash from operations	264	(1,264)	(1,502)	(347)	(728)	(122)
Investing						
Capital expenditure	(615)	(756)	(769)	(600)	(400)	(200)
Acquisition of subsidiaries/ investments	0	(1,905)	(1,039)	0	0	0
Net proceeds from disposal of short-term investments	0	1,846	974	0	0	0
Others	(23)	(27)	17	(83)	(83)	(83)
Net cash from investing	(638)	(842)	(818)	(683)	(483)	(283)
Financing						
Dividend paid	0	0	0	0	0	0
Net borrowings	(108)	0	1,126	1,500	1,500	500
Proceeds from share issues	(14)	2,520	0	0	0	0
Share repurchases	(449)	(41)	(99)	0	0	0
Others	(55)	(52)	(82)	(65)	(114)	(146)
Net cash from financing	(627)	2,427	944	1,435	1,386	354
Net change in cash						
Cash at the beginning of the year	2,769	1,757	2,069	727	1,131	1,306
Exchange difference	(10)	(9)	(1)	0	0	0
Cash at the end of the year	1,757	2,069	692	1,131	1,306	1,254
GROWTH	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
Revenue	na	(46.1%)	40.2%	61.7%	51.4%	50.0%
Gross profit	na	(63.3%)	65.3%	69.8%	53.0%	49.4%
PROFITABILITY	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
Gross profit margin	95.3%	64.8%	76.5%	80.3%	81.2%	80.8%
Operating margin	19.8%	(129.2%)	(138.3%)	(69.2%)	(32.4%)	(3.3%)
Return on equity (ROE)	7.8%	(23.7%)	(35.9%)	(44.6%)	(53.3%)	(21.5%)
GEARING/LIQUIDITY/ACTIVITIES	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
Current ratio (x)	3.7	3.6	2.0	1.8	2.1	2.1
VALUATION	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
P/E	26.7	ns	ns	ns	ns	ns

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.